Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chordia TherapeuticsTSE:190A 12 Buyback Yield % is -8.80 as of Aug. 04, 2026. GuruFocus rates TSE:190A with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Chordia Therapeutics ranks better than 51.29% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Chordia Therapeutics Buyback Yield % Related Terms
Chordia Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Chordia Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:190A vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Chordia Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordia Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Chordia Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chordia Therapeutics (TSE:190A) has a Buyback Yield % of -8.80 as of Aug. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #358 out of 735 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Chordia Therapeutics' Buyback Yield % too high?
Chordia Therapeutics' current Buyback Yield % is -8.80. Based on the distribution chart, Chordia Therapeutics ranks #358 out of 735 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chordia Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #358 out of 735 companies for Buyback Yield %. This puts Chordia Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current Buyback Yield % is -8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Buyback Yield % of -8.80. The current Buyback Yield % is -8.80. Chordia Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Buyback Yield % is -8.80 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
12GF Score
Get the complete analysis for TSE:190A
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:190A has been successfully added to your 
